2. Cho KS. Tuberculosis control in the Republic of Korea. Epidemiol Health 2018;40:e2018036. PMID: 30081621.

3. Kim JH, Yim JJ. Achievements in and challenges of tuberculosis control in South Korea. Emerg Infect Dis 2015;21:1913-1920. PMID: 26485188.

4. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015;372:2127-2135. PMID: 26017823.

5. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers 2016;2:16076PMID: 27784885.

6. Lee SH. Tuberculosis infection and latent tuberculosis. Tuberc Respir Dis 2016;79:201-206.

7. Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. Arch Intern Med 2008;168:1984-1992. PMID: 18852399.

8. Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS One 2011;6:e22927. PMID: 21829557.

9. Kim SJ, Bai GH, Hong YP. Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis 1997;1:302-308. PMID: 9432384.

10. Kim SJ, Hong YP. Drug resistance of Mycobacterium tuberculosis in Korea. Tuber Lung Dis 1992;73:219-224. PMID: 1477389.

11. Hong YP, Kim SJ, Kwon DW, Chang SC, Lew WJ, Han YC. The sixth Nationwide Tuberculosis Prevalence Survey in Korea, 1990. Tuber Lung Dis 1993;74:323-331. PMID: 8292205.

12. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11:571-576. PMID: 17439684.

13. Kim J, Park YJ, Lee NY, Chang CL, Lee M, Shin JH. Anti-tuberculosis drug resistant rates in Mycobacterium tuberculosis Isolated from respiratory specimens: a multicenter study in Korea. Ann Clin Microbiol 2013;16:1-7.

14. Kim H, Mok JH, Kang B, Lee T, Lee HK, Jang HJ, et al. Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study. Korean J Intern Med 2019;34:344-352. PMID: 30045614.

15. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 1993;270:65-68. PMID: 8510299.

16. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000;283:2537-2545. PMID: 10815117.

17. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009;6:e1000146. PMID: 19753109.

18. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009;6:e1000150. PMID: 20101802.

19. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423-430. PMID: 2420242.

20. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987;136:1339-1342. PMID: 2891333.

21. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis 2012;16:812-816. PMID: 22507372.

22. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis 2017;17:223-234. PMID: 27865891.

23. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662. PMID: 12588714.

26. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis (emergency update 2008) [Internet]. Geneva: World Health Organization; 2008. cited 2019 Jun 1. Available from: https://apps.who.int/iris/handle/10665/43965. 27. Escalante P, Graviss EA, Griffith DE, Musser JM, Awe RJ. Treatment of isoniazid-resistant tuberculosis in southeastern Texas. Chest 2001;119:1730-1736. PMID: 11399698.

28. Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Lim SY, et al. Treatment of isoniazid-resistant pulmonary tuberculosis. BMC Infect Dis 2008;8:6PMID: 18211720.

29. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009;48:179-185. PMID: 19086909.

30. Bang D, Andersen PH, Andersen AB, Thomsen VO. Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. J Infect 2010;60:452-457. PMID: 20347869.

31. Munang ML, Kariuki M, Dedicoat M. Isoniazid-resistant tuberculosis in Birmingham, United Kingdom, 1999-2010. QJM 2015;108:19-25. PMID: 24989780.

32. Romanowski K, Chiang LY, Roth DZ, Krajden M, Tang P, Cook VJ, et al. Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada. BMC Infect Dis 2017;17:604PMID: 28870175.

33. Stagg HR, Harris RJ, Hatherell HA, Obach D, Zhao H, Tsuchiya N, et al. What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Thorax 2016;71:940-949. PMID: 27298314.

34. Stagg HR, Lipman MC, McHugh TD, Jenkins HE. Isoniazid-resistant tuberculosis: a cause for concern? Int J Tuberc Lung Dis 2017;21:129-139. PMID: 28234075.

35. Stagg HR, Bothamley GH, Davidson JA, Kunst H, Lalor MK, Lipman MC, et al. Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. Eur Respir J 2019;54:1900982. PMID: 31371444.

36. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med 2018;6:265-275. PMID: 29595509.

38. Stewart SM, Crofton JW. The clinical significance of low degrees of drug resistance in pulmonary tuberculosis. Am Rev Respir Dis 1964;89:811-829. PMID: 14169411.

40. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-593. PMID: 1501713.

41. Piatek AS, Telenti A, Murray MR, El-Hajj H, Jacobs WR Jr, Kramer FR, et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 2000;44:103-110. PMID: 10602730.

42. Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, Wanger A, et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:1241-1250. PMID: 12654653.

43. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79:3-29. PMID: 10645439.

44. Dalla Costa ER, Ribeiro MO, Silva MS, Arnold LS, Rostirolla DC, Cafrune PI, et al. Correlations of mutations in katG, oxyRahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol 2009;9:39PMID: 19228426.

45. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-230. PMID: 8284673.

46. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965;92:687-703. PMID: 5321145.

47. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2:10-15. PMID: 9562106.

48. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995;332:336-337.

49. Moore M, Onorato IM, McCray E, Castro KG. Trends in drugresistant tuberculosis in the United States, 1993-1996. JAMA 1997;278:833-837. PMID: 9293991.

50. Forssbohm M, Loddenkemper R, Rieder HL. Isoniazid resistance among tuberculosis patients by birth cohort in Germany. Int J Tuberc Lung Dis 2003;7:973-979. PMID: 14552568.

51. Fox L, Kramer MR, Haim I, Priess R, Metvachuk A, Shitrit D. Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis 2011;30:863-867. PMID: 21431989.

52. Bass JB Jr, Farer LS, Hopewell PC, O’Brien R, Jacobs RF, Ruben F, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149:1359-1374. PMID: 8173779.

53. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-548. PMID: 9797751.

54. National Collaborating Centre for Chronic Conditions. Centre for Clinical Practice at NICE. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence; 2011. 55. National Institute for Health and Care Excellence. Tuberculosis: NICE guideline (NG33) [Internet]. London: National Institute for Health and Care Excellence; 2016. cited 2019 Jun 1. Available from: https://www.nice.org.uk/guidance/ng33. 56. Tam CM, Chan SL, Lam CW, Leung CC, Kam KM, Morris JS, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med 1998;157(6 pt 1):1726-1733. PMID: 9620898.

57. Bai KJ, Yu MC, Suo J, Chiang CY, Chiang IH, Lin TP, et al. Short-course chemotherapy for isoniazid-resistant pulmonary tuberculosis. J Formos Med Assoc 1998;97:278-282. PMID: 9585680.

58. Babu Swai O, Aluoch JA, Githui WA, Thiong’o R, Edwards EA, Darbyshire JH, et al. Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. Tubercle 1988;69:5-14. PMID: 3051607.

59. Ormerod LP, Horsfield N, Green RM. Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started? J Infect 2001;42:1-3. PMID: 11243745.

60. Nolan CM, Goldberg SV. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Int J Tuberc Lung Dis 2002;6:952-958. PMID: 12475140.

61. Tuberculosis Research Centre. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 1997;1:509-517. PMID: 9487448.

62. Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 2004;39:1321-1328. PMID: 15494909.

63. Wang TY, Lin SM, Shie SS, Chou PC, Huang CD, Chung FT, et al. Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. PLoS One 2014;9:e86316. PMID: 24466020.

64. Baez-Saldana R, Delgado-Sanchez G, Garcia-Garcia L, Cruz-Hervert LP, Montesinos-Castillo M, Ferreyra-Reyes L, et al. Isoniazid mono-resistant tuberculosis: impact on treatment outcome and survival of pulmonary tuberculosis patients in Southern Mexico 1995-2010. PLoS One 2016;11:e0168955. PMID: 28030600.

65. Deepa D, Achanta S, Jaju J, Rao K, Samyukta R, Claassens M, et al. The impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of Andhra Pradesh, India. PLoS One 2013;8:e76189. PMID: 24146839.

66. Koh WJ, Kwon OJ, Park YK, Lew WJ, Bai GH. Development of multidrug resistance during treatment of isoniazid-resistant tuberculosis. Eur Respir J 2005;26:557PMID: 16135740.

67. Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy. Int J Tuberc Lung Dis 2001;5:40-45. PMID: 11263515.

68. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 2011;53:369-372. PMID: 21810750.

69. Lee H, Jeong BH, Park HY, Jeon K, Huh HJ, Lee NY, et al. Treatment outcomes with fluoroquinolone-containing regimens for isoniazid-resistant pulmonary tuberculosis. Antimicrob Agents Chemother 2016;60:471-477. PMID: 26525801.

70. Chien JY, Chen YT, Wu SG, Lee JJ, Wang JY, Yu CJ. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect 2015;21:59-68. PMID: 25636929.

71. Villegas L, Otero L, Sterling TR, Huaman MA, Van der, Gotuzzo E, et al. Prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru. PLoS One 2016;11:e0152933. PMID: 27045684.

72. Cornejo Garcia JG, Alarcon Guizado VA, Mendoza Ticona A, Alarcon E, Heldal E, Moore DA. Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014. PLoS One 2018;13:e0206658. PMID: 30513085.

74. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-280. PMID: 19406981.

75. Ramachandran G, Hemanth Kumar AK, Srinivasan R, Geetharani A, Sugirda P, Nandhakumar B, et al. Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. Indian J Med Res 2012;136:979-984. PMID: 23391793.

76. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101-119. PMID: 9068926.

77. Centers for Disease Control and Prevention (CDC). Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations: United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50:733-735. PMID: 11787580.

78. Lempens P, Meehan CJ, Vandelannoote K, Fissette K, de Rijk P, Van Deun A, et al. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci Rep 2018;8:3246PMID: 29459669.